Advanced Mesenchymal Enhanced Cell THerapY for SepTic Patients
Latest Information Update: 28 Mar 2024
At a glance
- Drugs GEM 00220 (Primary)
- Indications Bacterial infections; Septic shock
- Focus Adverse reactions
- Acronyms AMETHYST
- Sponsors Northern Therapeutics
- 28 Mar 2024 Status changed from active, no longer recruiting to discontinued.
- 06 Dec 2023 Planned End Date changed from 1 May 2025 to 1 Jan 2024.
- 06 Dec 2023 Status changed from recruiting to active, no longer recruiting.